BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28413029)

  • 1. Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis.
    Brown BA; Williams H; George SJ
    Prog Mol Biol Transl Sci; 2017; 147():197-237. PubMed ID: 28413029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
    Ruddy JM; Ikonomidis JS; Jones JA
    J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers.
    Skjøt-Arkil H; Barascuk N; Register T; Karsdal MA
    Assay Drug Dev Technol; 2010 Oct; 8(5):542-52. PubMed ID: 20662734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
    Johnson JL
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloproteinases promote plaque rupture and myocardial infarction: A persuasive concept waiting for clinical translation.
    Newby AC
    Matrix Biol; 2015; 44-46():157-66. PubMed ID: 25636537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
    George SJ
    Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Matrix metalloproteinases and atherosclerosis].
    Fic P; Zakrocka I; Kurzepa J; Stepulak A
    Postepy Hig Med Dosw (Online); 2011 Jan; 65():16-27. PubMed ID: 21357991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
    Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
    Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases in atherothrombosis.
    Bäck M; Ketelhuth DF; Agewall S
    Prog Cardiovasc Dis; 2010; 52(5):410-28. PubMed ID: 20226959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
    Olejarz W; Łacheta D; Kubiak-Tomaszewska G
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metalloproteinases in atherosclerosis.
    Johnson JL
    Eur J Pharmacol; 2017 Dec; 816():93-106. PubMed ID: 28893577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
    Rouis M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques.
    Schäfers M; Schober O; Hermann S
    J Nucl Med; 2010 May; 51(5):663-6. PubMed ID: 20439506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
    Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and atherosclerosis.
    Watanabe N; Ikeda U
    Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling.
    Myasoedova VA; Chistiakov DA; Grechko AV; Orekhov AN
    J Mol Cell Cardiol; 2018 Oct; 123():159-167. PubMed ID: 30172754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular extracellular matrix in atherosclerosis.
    Chistiakov DA; Sobenin IA; Orekhov AN
    Cardiol Rev; 2013; 21(6):270-88. PubMed ID: 23422022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability.
    Xie S; Nie R; Wang J
    J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability.
    Newby AC
    Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2108-14. PubMed ID: 18772495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
    Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
    Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.